Blair Westerly, MD
Pulmonary Disease · Des Moines, IANPI 1366685190
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (44.4%), education and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 88.3% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2020 at $4,730 and has fallen 99.0% since, to $48 in 2025.
Across 38 payments — averaging $185.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$6K
- Johnson & Johnson$558
- La Jolla Pharmaceutical Company$105
- ERBE USA Inc$56
- Amgen$48
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$22
- plus $38 from 2 others
What the payments were for
- Travel & lodging$3,12944%
- Food & beverage$91913%
- Education$3,00043%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 29 | $6,221 |
| Johnson & Johnson | 2 | $558 |
| La Jolla Pharmaceutical Company | 1 | $105 |
| ERBE USA Inc | 1 | $56 |
| Amgen | 2 | $48 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $22 |
| Mylan Specialty L.p. | 1 | $21 |
| Boehringer Ingelheim | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$5,420
- MONARCH$483
- GIAPREZA$105
How this compares
$7,048 in reported general payments places this provider in the 75th percentile of 110 pulmonary disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 36 | $496,409 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 145 | $107,037 |
| Breo ElliptaFluticasone/Vilanterol | 120 | $49,966 |
| Arnuity ElliptaFluticasone Furoate | 57 | $12,564 |
| Spiriva RespimatTiotropium Bromide | 18 | $11,475 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 24 | $11,444 |
| Advair HfaFluticasone Propion/Salmeterol | 19 | $10,953 |
| Incruse ElliptaUmeclidinium Bromide | 27 | $9,484 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 71 | $9,226 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $4,163 |
| Wixela InhubFluticasone Propion/Salmeterol | 14 | $1,955 |
| Ventolin HfaAlbuterol Sulfate | 35 | $1,950 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 75 | $1,707 |
| Fluticasone Propionate | 18 | $1,143 |
| Advair DiskusFluticasone Propion/Salmeterol | 11 | $915 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $17 | $519,32978 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 110 pulmonary disease providers in Iowa.
Other pulmonary disease in Des Moines
- Shrey VelaniDes Moines$18K
- Neil HorningDes Moines$15K
- Jason WittmerDes Moines$10K
- Bradley WilcoxDes Moines$7K
- Eric AsbeDes Moines$4K
- Maxwell CosmicDes Moines$3K
- Anthony GrecoDes Moines$3K
- Lucas Silqueira Hickson CruzDes Moines$2K
- Maksym PuliaievDes Moines$2K
- Bryon JohnsonDes Moines$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.